International Niemann–Pick Disease Alliance
INPDA has been informed by Sanofi of supply interruptions affecting Xenpozyme (olipudase alfa), a treatment for Acid Sphingomyelinase Deficiency (ASMD).
As of November 2026, Sanofi anticipates a shortage of olipudase alfa in some countries. Sanofi has also advised that, based on current supply forecasts and anticipated consumption, global supply of olipudase alfa is expected to become insufficient to meet global demand beginning in mid-2027.
We recognise that this news may cause concern and uncertainty for people living with ASMD and their families, particularly those who rely on regular treatment.
Sanofi has advised that it is working to manage global supply and minimise the impact on people living with ASMD. The company is also working to increase long-term production capacity and develop potential approaches intended to help preserve access to treatment for as many people as possible.
What should people currently receiving Xenpozyme do?
People receiving Xenpozyme who have questions or concerns about their treatment should contact their treating physician or specialist clinical team for individual advice.
What is INPDA doing?
As a global patient organisation, INPDA is engaging with Sanofi, our member organisations, the clinical community and other relevant stakeholders to better understand the situation and its impact on people living with ASMD around the world.
We are committed to advocating for the needs of people living with ASMD and their families, supporting clear and accurate communication, and helping to ensure that the experiences and concerns of the community are heard.
We are also considering how best to gather information about the experiences of people living with ASMD who may be affected by supply interruptions. Further information may be shared with the community as this work develops.
Further information:
For further information and updates regarding the Xenpozyme supply situation, please refer to information provided directly by Sanofi:
https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases/supply-update
INPDA will continue to monitor the situation and share relevant information with the international Niemann-Pick community as it becomes available.